Fingolimod Unknown Status Phase 4 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02325440Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya